This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E24.0 (Cushing disease) | Special Copayment Reduction: V114 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Pituitary-dependent Cushing's disease, Pituitary ACTH hypersecretion, Pituitary-dependent hypercortisolism, ACTH-secreting pituitary adenoma |
| C. Adult onset | Likelihood of first presentation in adulthood very high — most common in women in their 20s–40s, and diagnosis takes several years on average. |
| 1. History | Harvey Cushing described the association of basophilic pituitary adenoma with a hypercortisolism syndrome in 1912 → formal publication on Cushing disease (pituitary-dependent type) in 1932 → pathophysiology subsequently elucidated through the discovery and measurement of ACTH. |
| 2. Causes | ACTH hypersecretion by an ACTH-secreting adenoma of the anterior pituitary (mostly microadenomas, diameter <10 mm) → bilateral adrenal cortical hyperplasia → cortisol overproduction. |
| 3. Genetics | Mostly sporadic. USP8 and USP48 somatic variants frequently found in adenomas. MEN1 and CDKN1B variants rarely involved. Familial forms rare. |
| 4. General epidemiology | Incidence 1.2–2.4/million/year. Accounts for about 70–80% of Cushing syndrome. Female-to-male ratio about 3–4:1. Median age at diagnosis about 35–40 years. |
| 5. Pathophysiology | ACTH-secreting pituitary adenoma → excess ACTH → bilateral adrenal cortical hyperplasia → excess cortisol → failure of normal hypothalamic-pituitary-adrenal axis suppression (incomplete negative feedback). Abnormal USP8 activation causes EGFR signaling hyperactivity. |
| 6. Symptoms | Weight gain (central obesity), round face (moon face), buffalo hump, proximal muscle weakness, skin purpura and striae, hypertension, diabetes, osteoporosis, amenorrhea, mood disorders and depression. |
| 7. Signs | Purple striae on the abdomen and thighs (width 1 cm or more), proximal muscle weakness (quadriceps), plethora (multiple purpura), abnormal knee reflexes, persistently elevated serum cortisol, ACTH above measurable levels. |
| 8. Screening | ① 24-hour urinary free cortisol (UFC) ② late-night serum cortisol (midnight, >7.5 μg/dL) ③ 1 mg dexamethasone suppression test (08:00 cortisol >1.8 μg/dL). If 2 or more are positive, proceed to confirm Cushing syndrome. |
| 9. Diagnosis | Confirm hypercortisolism → serum ACTH (determine ACTH dependence) → 8 mg high-dose dexamethasone suppression test → pituitary MRI → inferior petrosal sinus sampling (IPSS). Exclude adrenal causes with adrenal CT. |
| 10. Treatment | First-line: transsphenoidal surgery. Second-line (failure or recurrence): reoperation, radiosurgery (Gamma Knife), adrenalectomy, drug therapy (pasireotide, ketoconazole, mitotane, metyrapone, osilodrostat). |
| 11. Prognosis | Remission rate after surgery 70–90% (microadenoma). Recurrence rate 15–25% (within 5–10 years). 5-year survival about 50% without treatment. Cardiovascular and infectious complications are the main causes of death. Cardiovascular risk persists even after remission. |
| 12. Prevention | Primary prevention impossible (cause of adenoma development unknown). Secondary prevention: early screening and diagnosis, postoperative cortisol monitoring. Tertiary prevention: early detection of recurrence, cardiovascular and osteoporosis management. |
| 13. References | Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations. 1932 … and 9 other papers |
The history of Cushing disease begins in the early 20th century with the clinical observations of an outstanding neurosurgeon, Harvey Williams Cushing (1869–1939). In his 1912 book The Pituitary Body and Its Disorders, Cushing described several patients with an abnormal body habitus (central obesity, round face, buffalo hump) and reported pituitary abnormalities in some of them. At the time, however, the functional connection between the pituitary and adrenal glands and even the existence of cortisol were unknown, and the cause of this syndrome remained unclear.
The decisive turning point came in 1932. In the paper "The basophil adenomas of the pituitary body and their clinical manifestations" published in the Bulletin of the Johns Hopkins Hospital, Cushing analyzed autopsy or surgical specimens from 12 patients and was the first to propose systematically that hyperplasia of basophil cells or adenoma of the anterior pituitary is the cause of this syndrome. By putting forward the hypothesis that a pituitary abnormality causes hyperplasia of the adrenal cortex and produces the clinical syndrome, he pointed out that the cause of this disease lies in the pituitary. The scientific community subsequently named this disease 'Cushing disease', and a nomenclature became established that distinguishes hypercortisolism from causes other than pituitary dependence (adrenal adenoma, ectopic ACTH secretion, etc.) as 'Cushing syndrome'.
From the 1940s onward, as ACTH (adrenocorticotropic hormone) was discovered and measurement techniques developed, the pathophysiology of Cushing disease gradually became clear. In 1952, Liddle et al. developed the dexamethasone suppression test, providing a key tool for differentiating pituitary-dependent Cushing disease from ectopic ACTH syndrome and primary adrenal causes. In the late 1970s, Corrigan et al. and Oldfield et al. developed inferior petrosal sinus sampling (IPSS), a technical advance that made it possible to determine tumor laterality even in patients with no lesion visible on MRI.
The history of surgical treatment entered a new phase in the 1960s–70s, when Hardy standardized transsphenoidal microsurgery. Previously adrenalectomy was the main treatment, but the introduction of transsphenoidal surgery to remove the adenoma directly opened an era of treatment that preserves pituitary function. Since the 2000s, somatic variants in the USP8 and USP48 genes have been identified as molecular causes of Cushing adenomas, stimulating research on targets for new drug development. Pasireotide was approved as a treatment for Cushing disease in Europe in 2012 and by the US FDA in 2014, expanding drug treatment options for patients with residual or recurrent disease after surgery.
The underlying cause of Cushing disease is an ACTH-secreting adenoma of the anterior pituitary (corticotroph adenoma). This adenoma autonomously secretes excess adrenocorticotropic hormone (ACTH), chronically stimulating both adrenal cortices and causing overproduction of cortisol. The cortisol excess persists because the normal negative feedback mechanism, which should in turn suppress pituitary ACTH secretion, does not work.
Adenomas are classified by size into microadenomas (diameter <10 mm) and macroadenomas (≥10 mm). About 80–90% of Cushing disease is caused by microadenomas, many of which are very small (2–6 mm in diameter), so about 30–40% are not detected on MRI. The remaining 10–20% are macroadenomas, which may be accompanied by mass effects such as visual field defects. In very few cases, pituitary carcinoma or hyperplasia is the cause.
At the molecular level, the somatic variants associated with Cushing adenoma formation that have drawn the most attention are activating variants of the USP8 (ubiquitin-specific protease 8) gene. USP8 variants are found in about 35–62% of Cushing adenomas in Western populations and in about 50% or more of adenomas in East Asia (including Korea and Japan). USP8 is a deubiquitinating enzyme that regulates ubiquitination and degradation of membrane receptors, including the epidermal growth factor receptor (EGFR); with activating variants, EGFR signaling persists, promoting proliferation of ACTH-secreting cells and POMC (pro-opiomelanocortin) transcription. In 2019, USP48 variants were also reported as an additional cause in some adenomas. In addition, CABLES1 inactivating variants, TP53 variants and BRAF V600E variants are rarely reported.
Abnormal pituitary stimulation by corticotropin-releasing hormone (CRH) hypersecretion is also mentioned as a rare cause of Cushing disease. In this case, corticotroph cell hyperplasia rather than an adenoma is observed in the pituitary. Thus Cushing disease is understood as the result of a multistep tumorigenesis process in adenoma cells rather than a single-gene abnormality.
The ACTH-secreting pituitary adenomas that cause Cushing disease are mostly sporadic, and hereditary forms due to germline mutations are rare. However, they can rarely occur as part of hereditary tumor syndromes such as multiple endocrine neoplasia type 1 (MEN1), familial isolated pituitary adenoma (FIPA) and Carney complex.
Among somatic mutations in adenoma tissue, USP8 is the most common. Classic hotspot variants located in exon 14 of the USP8 gene (15q21.2) (mainly p.Ser718Pro, p.Pro720Arg, p.Tyr719Cys) are found in more than 50% of adenomas. These variants alter the linker region between the SH3 domain and the USP8 catalytic domain, interfering with binding to 14-3-3 proteins and keeping USP8 in a hyperactive state. USP8-mutant adenomas are reported to have the clinical characteristics of being more common in women, with more severe cortisol hypersecretion, higher basal ACTH and a somewhat lower postoperative recurrence rate.
In MEN1 syndrome (MEN1 gene variants at 11q13, autosomal dominant), pituitary adenomas occur in about 40%, but a Cushing disease phenotype is rare, in fewer than 5% of these. MEN4, caused by variants in CDKN1B (encoding the p27 protein), is also associated with pituitary adenomas. Carney complex is caused by PRKAR1A gene variants; Cushing syndrome due to primary pigmented nodular adrenocortical disease (PPNAD) is the main endocrine abnormality, but pituitary adenomas rarely accompany it.
From a clinical genetics standpoint, germline genetic testing to exclude hereditary causes such as MEN1, MEN4 and AIP variants should be considered in young patients under 35, macroadenomas, an aggressive clinical course, or accompanying other endocrine tumors (parathyroid, pancreas, adrenal, etc.). When there is a family history, appropriate gene panel testing is performed after genetic counseling.
Cushing disease is the most common cause of endogenous Cushing syndrome, accounting for about 70–80% of all Cushing syndrome. The incidence is reported at about 1.2–2.4 per million population per year, and the prevalence is estimated at about 39–79 per million. Although rare, diagnosis is often delayed, so the actual prevalence is presumed to be higher than registry statistics. The combined prevalence of all endogenous Cushing syndrome is about 10–15 per million, of which the pituitary-dependent type is the most common.
In terms of sex and age, Cushing disease is 3–4 times more common in women than in men, and the median age at diagnosis is about 35–40 years. This may be related to the development of ACTH-secreting adenomas being influenced by sex hormones such as estrogen, or to USP8 variants in adenoma cells occurring more frequently in women. Occurrence in children is rare, but in pediatric Cushing syndrome the proportion of macroadenomas is higher than in adults.
Epidemiological data in Korea are limited, but studies using Health Insurance Review & Assessment Service (HIRA) data are determining the proportion of Cushing disease among patients visiting for endocrine diseases. Korean multicenter studies also confirm epidemiological features of female predominance and microadenoma predominance, similar to Western reports. The status of management in Korea can be indirectly determined from the number of patients registered under Special Copayment Reduction V114. Diagnostic delay is typically several years, and Korean experience is consistent with international reports of a mean diagnostic delay of 4–5 years.
When Cushing disease is untreated or incompletely treated, mortality from cardiovascular disease, infection and thromboembolism is known to increase up to about 4 times that of the general population. This supports the clinical importance of early diagnosis and aggressive treatment.
The pathophysiology of Cushing disease can be summarized as chronic hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis centered on an ACTH-secreting pituitary adenoma. Normally, the HPA axis is tightly regulated by negative feedback from cortisol. That is, when blood cortisol rises, CRH secretion by the hypothalamus and ACTH secretion by the pituitary are suppressed, normalizing the HPA axis. However, the adenoma cells of Cushing disease are resistant to this negative feedback (glucocorticoid resistance), so they continue to secrete ACTH autonomously no matter how high cortisol rises.
At the molecular level, EGFR signaling hyperactivity due to activating USP8 variants plays an important role. Normally, USP8 removes ubiquitin from EGFR, delaying lysosomal degradation; mutant USP8 has increased deubiquitinating activity, so EGFR remains on the membrane surface longer. This persistent EGFR signal promotes transcription of the POMC (pro-opiomelanocortin) gene and induces corticotroph cell proliferation, leading to adenoma formation and ACTH hypersecretion.
The excess ACTH is released into the blood and continuously stimulates both adrenal cortices, especially the zona fasciculata. As a result, both adrenal cortices undergo diffuse hyperplasia (bilateral adrenal hyperplasia), and cortisol production increases markedly. This chronic hypercortisolism causes various pathophysiologic changes throughout the body. In adipose tissue, lipolysis is promoted and fat is redistributed centrally, increasing abdominal and visceral fat, whereas the limb muscles atrophy because of increased protein breakdown. In bone, suppression of osteoblast function and activation of osteoclasts lead to progressive osteoporosis, and the skin thins because of breakdown of dermal proteins, making blood vessels easily visible and forming purple striae.
In terms of endocrine metabolism, cortisol causes insulin resistance, leading to diabetes or impaired glucose tolerance, and activates the renin-angiotensin-aldosterone system, causing hypertension. Its immunosuppressive effect increases vulnerability to opportunistic infections, and its promotion of coagulation factor production increases the risk of thromboembolism. All these changes explain the complex clinical phenotype and high complication rate of Cushing disease.
The clinical symptoms of Cushing disease reflect multiorgan involvement due to chronic hypercortisolism; most progress gradually over months to years and may appear nonspecific at first. The most prominent symptom is weight gain (central obesity), with fat concentrated in the abdomen and viscera, a rounded 'moon face', and a 'buffalo hump' forming at the back of the neck and between the shoulder blades. In contrast, the arms and legs become thin because of muscle atrophy, producing a characteristic disproportionate body shape.
Skin changes include violaceous striae 1 cm or more wide on the abdomen, thighs, axillae, breasts and elsewhere, and the skin becomes thin so that bruising (purpura) easily occurs with minor trauma. Facial plethora and acne are also commonly observed. In women, hirsutism (male-pattern body hair distribution due to androgen excess) may develop.
Musculoskeletal symptoms characteristically include proximal muscle weakness (proximal myopathy), making it difficult to climb stairs or rise from a chair. Low back pain and vertebral compression fractures due to chronic osteoporosis occur in a considerable number of patients, and some notice a loss of height.
Metabolic and cardiovascular symptoms include hypertension, diabetes or impaired glucose tolerance, dyslipidemia and a tendency to thromboembolism (increased risk of DVT and pulmonary embolism). In women, amenorrhea or irregular menstruation is common, accompanied by decreased libido due to hypogonadism. Neuropsychiatric symptoms such as depression, anxiety, cognitive decline and insomnia are very common and seriously affect quality of life. Because of immunosuppression, patients are vulnerable to opportunistic infections such as cutaneous dermatophytosis, oral candidiasis and pneumonia, and wound healing is poor.
Among the physical examination findings of Cushing disease, the most specific is violaceous striae (1 cm or more wide), which, unlike the white striae of pregnancy or obesity, are reddish purple and markedly wide. Together with this, the combination of central obesity (increased waist-to-hip ratio) and proximal muscle weakness is one of the key triads for the clinical diagnosis of Cushing disease. In quadriceps strength testing, inability to rise from a chair without using the arms is an objective indicator.
Skin findings include plethora (facial flushing), easy skin bruising, decreased skin thickness (easily pinched up) and hirsutism (in women). Apart from facial obesity, a characteristic facial appearance due to temporal fat accumulation appears. Supraclavicular fat pads and dorsal kyphosis may also be observed.
Laboratory findings show plasma ACTH maintained above measurable levels (generally in the 10–200 pg/mL range), and 24-hour urinary free cortisol (UFC) rises to 3 or more times the upper limit of normal. Hypokalemia (severe especially in the ectopic ACTH form but also present in Cushing disease), hyperglycemia, erythrocytosis, leukocytosis and decreased lymphocytes and eosinophils accompany it. On the dexamethasone suppression test, suppression of serum cortisol by 50% or more after a high dose (8 mg) is the characteristic response of Cushing disease. Pituitary MRI reveals a microadenoma, but MRI is negative in about 30–40%.
The principle of screening for Cushing disease (Cushing syndrome) is to identify patients with hypercortisolism among patients with nonspecific symptoms. The currently recommended first-line screening tests are the following three; if two or more are positive, confirmatory testing for Cushing syndrome proceeds.
First, 24-hour urinary free cortisol (UFC): reflects the total amount of unbound cortisol filtered by the kidneys. A rise to 3 or more times the upper limit of normal (generally 50–100 μg/24h, varying by institution) is meaningful. Its drawbacks are low sensitivity (about 45–71%) and possible false positives due to polyuria or high fluid intake.
Second, late-night salivary cortisol (LNSC): detects loss of the normal diurnal cortisol pattern, in which midnight should be the nadir. It is a noninvasive method that can be collected at home and is highly convenient. Two repeated measurements are recommended.
Third, the overnight 1 mg dexamethasone suppression test (overnight 1 mg DST): dexamethasone 1 mg is taken orally at 11 p.m. the night before, and serum cortisol is measured at 8 a.m. the next morning. A cortisol of 1.8 μg/dL or higher is judged positive. It is a highly sensitive test, but its specificity is low (false positives about 15–30%), so confirmatory testing is needed. Use of exogenous steroids, use of CYP3A4 inducers (rifampin, antiepileptics) and high-estrogen states can distort the results.
Before screening, differentiation from conditions causing pseudoCushing's syndrome (depression, alcohol dependence, obesity, chronic stress) is important; in such cases, the dexamethasone suppression test followed by CRH stimulation (Dex-CRH test) or the insulin-induced hypoglycemia test may additionally be used.
Diagnosis of Cushing disease follows a stepwise approach: confirmation of hypercortisolism → determination of ACTH dependence → localization of the source (pituitary vs. ectopic).
Step 1: confirmation of hypercortisolism. If two or more screening tests are positive, endogenous Cushing syndrome is diagnosed. Causes of false positives, including use of exogenous steroids, must be systematically excluded.
Step 2: determination of ACTH dependence. Plasma ACTH measured at 8 a.m. ACTH <5 pg/mL → ACTH-independent (primary adrenal cause) → adrenal CT. ACTH ≥10 pg/mL → ACTH-dependent → proceed to the next step.
Step 3: Cushing disease vs. ectopic ACTH. High-dose dexamethasone suppression test (8 mg overnight DST or 2-day high-dose DST): in Cushing disease, cortisol is suppressed by 50% (80% by some criteria) or more from baseline, whereas there is no suppression in ectopic ACTH syndrome. However, false positives and false negatives occur, so IPSS is the gold standard. Inferior petrosal sinus sampling (IPSS): ACTH is sampled simultaneously from both inferior petrosal sinuses and peripheral blood, and the ratios are compared (central:peripheral basal ratio ≥2.0, ≥3.0 after CRH stimulation). In Cushing disease, the central:peripheral ratio exceeds the threshold, whereas it is low in ectopic ACTH. Comparison of the two sides on IPSS also predicts the laterality of the adenoma.
Pituitary MRI: a 3T MRI dynamic contrast-enhanced protocol is recommended. Finding a microadenoma supports the diagnosis, but even if MRI is negative, transsphenoidal surgery proceeds if IPSS results are clear. The possibility of false-positive MRI (nonfunctioning adenoma, Rathke cyst) must also be considered.
The first-line treatment of Cushing disease is removal of the adenoma by transsphenoidal surgery (TSS). With microsurgery or endoscopic surgery by an experienced neurosurgeon, remission rates of 70–90% for microadenomas and 50–70% for macroadenomas can be expected. The indicator of surgical success is a fall in postoperative serum cortisol to below 2 μg/dL (adrenal insufficiency). Hydrocortisone replacement is needed for 6–18 months after surgery until adrenal function recovers.
If surgery fails or the disease recurs, the optimal second-line treatment is chosen according to the patient's situation from reoperation, radiation therapy, bilateral adrenalectomy and drug therapy. With radiosurgery (Gamma Knife, CyberKnife), the cortisol-suppressing effect on residual adenoma appears over 2–5 years, with a remission rate of about 45–80%. Bilateral adrenalectomy provides rapid and definite correction of hypercortisolism but requires lifelong management of adrenal insufficiency and carries the risk of Nelson syndrome.
Drug therapy is used to lower cortisol levels before surgery, when surgery is not possible, or while waiting in cases of recurrence. Pasireotide (a somatostatin receptor ligand, given subcutaneously or as a long-acting intramuscular injection), which suppresses ACTH secretion at the pituitary level, is an FDA-approved drug, but hyperglycemia is a common adverse effect. Drugs that inhibit adrenal cortisol synthesis include ketoconazole, metyrapone, mitotane and osilodrostat. The glucocorticoid receptor antagonist mifepristone controls some clinical effects of cortisol excess (insulin resistance, psychiatric symptoms).
The prognosis of Cushing disease depends greatly on whether treatment succeeds. Past studies show that if left untreated, 5-year survival is only about 50% because of cardiovascular disease, diabetes, thromboembolism and infectious complications due to chronic hypercortisolism. When hypercortisolism is corrected with appropriate treatment, most complications recover partially or completely.
The initial remission rate after transsphenoidal surgery is 70–90% for microadenomas and 50–70% for macroadenomas, but on long-term follow-up the recurrence rate reaches about 15–25% within 5–10 years. The lower the postoperative cortisol nadir, the lower the risk of recurrence, and the best prognosis is seen when both ACTH and cortisol fall to undetectable levels after surgery. For early detection of recurrence, regular follow-up with UFC, salivary cortisol and pituitary MRI is needed even after remission.
Studies show that cardiovascular risk remains persistently higher than in the general population even after remission. Hypertension, diabetes and dyslipidemia improve partially after remission but often do not fully normalize, so active management of cardiovascular risk factors is needed. Bone density recovers slowly after remission, but vertebral compression fractures that have already occurred are difficult to reverse. Recovery of cognitive function and quality of life may also be delayed in proportion to the duration of exposure to long-term hypercortisolism. To prevent Nelson syndrome, some centers use a strategy of performing pituitary radiation therapy in advance after bilateral adrenalectomy.
Because the underlying cause of the ACTH-secreting adenomas that cause Cushing disease (somatic variants such as USP8) cannot currently be prevented, primary prevention is practically impossible. However, secondary and tertiary prevention to prevent complications and detect recurrence early are clinically very important.
The key to secondary prevention (early detection) is actively including Cushing syndrome in the differential diagnosis of patients with nonspecific symptoms of Cushing syndrome (hypertension, diabetes, obesity, osteoporosis, depression). In particular, unexplained osteoporosis at a young age, or obesity with purple striae or proximal muscle weakness, should prompt early referral to endocrinology. Appropriate use of screening tests (UFC, LNSC, 1 mg DST) is key to shortening diagnostic delay.
For tertiary prevention of postoperative recurrence, UFC, late-night salivary cortisol and plasma ACTH are followed every 6 months to 1 year for at least 10 years after remission. If postoperative cortisol levels show a rising trend, pituitary MRI and additional dynamic testing are performed promptly. Cardiovascular risk factors (blood pressure, blood glucose, lipids, weight) and bone density should be continuously monitored and actively managed even after remission. Regular endocrine screening of family members of patients suspected of having hereditary tumor syndromes such as MEN1 and FIPA is also an important preventive strategy.